IRCT20200105046010N78招募中Unknown
Bioequivalence study of Ibrutinib 140 mg capsule (Lifoza) manufactured by Dr. Abidi company versus Imbruvica 140 mg in healthy volunteers in the fasted condition
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcohol and drug addiction
- •History of allergy to Ibrutinib
研究者
相似试验
招募中
Unknown
In-vivo Bioequivalence Study of Ibrutinib 140 mg capsule of The Test Drug (ACTLOUVIKA®, 140 mg , Actero Pharma, Iran)This study is performed on healthy volunteers and drug concentration in plasma is determined..IRCT20200105046010N111Actro Middle East Pharmaceutical Co24
尚未招募
不适用
Study of absorption and elimination rate of Ibrutinib 140 -mg Capsules in comparison with Ibrutinib brand capsules (Imbruvica®)IRCT20200407046981N43Kimia pharmaceutical Co24
进行中（未招募）
1 期
A study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Multiple Myeloma PatientsEUCTR2015-005105-36-CZPharmacyclics Switzerland GmbH125
进行中（未招募）
1 期
A study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Multiple Myeloma PatientsRelapsed or Relapsed and Refractory Multiple Myeloma (MM)MedDRA version: 19.0 Level: LLT Classification code 10028228 Term: Multiple myeloma System Organ Class: 100000004864EUCTR2015-005105-36-PLPharmacyclics Switzerland GmbH125
进行中（未招募）
1 期
A study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Multiple Myeloma PatientsRelapsed or Relapsed and Refractory Multiple Myeloma (MM)MedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2015-005105-36-ITPHARMACYCLICS, INC.74